<DOC>
	<DOCNO>NCT00080483</DOCNO>
	<brief_summary>Deficiency testosterone , growth hormone , hormone result osteoporosis . If either hormone replace , condition bone improves . The purpose study determine dual hormone treatment men deficient testosterone growth hormone improve bone structure testosterone treatment alone .</brief_summary>
	<brief_title>Testosterone Growth Hormone Bone Loss Men</brief_title>
	<detailed_description>Replacement testosterone growth hormone patient deficient improves osteoporosis associate deficiency . In tissue , muscle , effect testosterone growth hormone additive , know effect additive bone well . This study compare effect testosterone alone testosterone plus growth hormone improve bone structure men total pituitary hormone deficiency . Participants study men pituitary hypothalamic disease deficiency pituitary hormone , treat either testosterone growth hormone . The men randomly assign receive either testosterone alone testosterone plus growth hormone two year . Testosterone gel form apply daily skin . Growth hormone self-administered daily subcutaneous injection . Blood concentration hormone monitor blood test every 3 month 2-year study . Doses hormone adjust keep blood concentration hormone within normal range . Changes bone structure assess noninvasively treatment one year two year treatment magnetic resonance microimaging ( ÂµMRI ) dual energy X-ray absorptiometry ( DEXA ) .</detailed_description>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Hypopituitarism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Documented hypothalamic pituitary hormone deficiency Testosterone deficiency , define total serum testosterone less 250 ng/dL two 8 AM reading Growth hormone deficiency , define either follow : For subject thyroxine cortisol deficiency , either subnormal agespecific IGF1 peak GH response arginineGHRH le 4.1 ng/mL For subject thyroxine cortisol deficiency , either subnormal agespecific IGF1 peak GH response arginineGHRH le 4.1 ng/mL Duration testosterone growth hormone deficiencies two year Replacement cortisol and/or thyroxine deficiency Able give inform consent Current testosterone treatment treatment two year prior study entry Current growth hormone treatment treatment three year prior study entry Use prescription overthecounter androgen ( androstenedione , DHEA ) , estrogens , antiandrogens ( spironolactone , ketoconazole ) Diseases could influence bone , hyperparathyroidism Medications could influence bone , anticonvulsant glucocorticoid ( prednisone great 20 mg/day long 2 weeks/year ) . Calcium overthecounter vitamin D supplement allow . Cancer could limit life expectancy few 5 year Neuromuscular disease history stroke residual neurological defect Severe uncontrolled psychiatric illness dementia Noncancerous enlargement prostate gland ( American Urological Association symptom score great 21 ) Prostate cancer history , prostate nodule digital rectal exam ( DRE ) , prostate specific antigen ( PSA ) great 4 Current alcohol drug dependence Heart failure ( New York class III IV ) Unstable angina Myocardial infarction within 3 month study entry Liver disease ( ALT great 3 x normal ) Renal disease ( serum creatinine great 2.5 mg/dl ) Diabetes mellitus ( glycosolated hemoglobin great 8.0 % ) Hypertension ( systolic BP great 160 diastolic BP great 100 mm Hg ) Hematocrit great 48 % Weight great 300 pound Poor quality scan baseline even repeat Untreated , severe , obstructive sleep apnea ( Epworth sleepiness score great 10 ) Unable undergo MRI cardiac pacemaker ferrometallic object body</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>